INSUBCONTINENT EXCLUSIVE:
Apart from the Oxford candidate, two more vaccine candidates in India are in advanced stages of clinical trials, while
four are in pre-clinical development stage
India's single-day recovery exceeded the number of new infections as nearly
96,000 people recuperated from the novel coronavirus, even as the total caseload went past 53 lakh, according to the Union Health Ministry
data updated on Saturday.With this, the country also crossed United States to register the highest number of COVID-19 recoveries in the
world.The figures released at 8 am Saturday showed that while 95,880 people recovered from COVID-19 in a span of 24 hours, 93,337 new
hours, the updated data showed.The 1,247 new deaths reported on Saturday include 440 from Maharashtra, 179 from Karnataka, 98 from Uttar
Pradesh, 67 each from Andhra Pradesh and Tamil Nadu, 62 from Punjab, 59 from West Bengal, 31 from Puducherry and 30 from Delhi.The COVID-19
case fatality rate has further dropped at 1.61 percent
There are 10,13,964 active cases of COVID-19 in the country, which constitute 19.10 percent of the total caseload, the data stated.The
worst-hit states are Maharashtra (11,88,015) Andhra Pradesh (6,17,776), Tamil Nadu (5,36,000), Karnataka (5,11,000), and UP (3,48,517).Phase
III clinical trial of Oxford's vaccine candidate to begin from MondaySerum Institute of India (SII), will begin the phase III human trials
of Oxford University's COVID-19 vaccine at the Sassoon General Hospital in Pune next week
Furthermore, the Central Government said that two other vaccine candidates in India were at advanced stages of testing."The phase III trial
of Covishield vaccine will begin at Sassoon hospital from next week
It is likely to start on Monday (21 September)
Some volunteers have already come forward for the trial
with British-Swedish pharma company AstraZeneca for manufacturing the COVID-19 vaccine candidate, developed by the University of
Oxford.Apart from the Oxford candidate, two more vaccine candidates in India are in advanced stages of clinical trials, while four are in
pre-clinical development stage, Health Minister Harsh Vardhan said on Friday in a written reply to a question in Lok Sabha
developed by the Tata Group and CSIR-IGIB, was approved for use in India, the Ministry of Science and Technology said on Saturday.According
The equipment are also less expensive."Tata CRISPR COVID-19 test uses an indigenously developed, cutting-edge CRISPR technology for
detection of the genomic sequence of SARS-CoV-2 virus," the report said.Over 190% rise in active Covid-19 cases in Delhi in a monthThe
number of active COVID-19 cases in Delhi increased by around 190 percent in a month with 84,087 people contracting the disease during the
period, according to government data.There were 11,068 active COVID-19 cases on 18 August
The number increased to a record 32,250 on Friday, an analysis of Delhi government's health bulletins showed.A similar trend was witnessed
in June, when the number of active COVID-19 cases rose from 11,555 on 1 June to 28,329 on 27 June
It, however, tapered off to 10,705 active cases by 31 July.On 4 August, it dropped below the 10,000-mark for the first time since 30 May and
stood at 9,897, owing to a good recovery rate and less new cases.But just when it seemed the number might drop further, it started rising
again with an increase in new cases.Parliament Monsoon Session likely to be curtailed due to COVID-19 spreadThe ongoing monsoon session of
Parliament is likely to be curtailed and may end by the middle of next week in view of the threat of the COVID-19 spread among
parliamentarians, official sources said on Saturday.At a meeting of the business advisory committee of Lok Sabha, which has floor leaders of
all parties besides the government representatives and is chaired by the Speaker, most political parties favoured curtailment of the
session, which started on 14 September and was scheduled to conclude on 1 October.After some Members of Parliament, including Union
ministers Nitin Gadkari and Prahlad Patel, tested positive for COVID-19 during the session, some opposition parties had conveyed to the
government that conducting the full 18-day session could be a risky affair, sources told PTI.A final decision will be taken by the Cabinet
Committee on Parliamentary Affairs.Centre expresses concern over higher fatality rate in 12 statesExpressing concern over COVID-19 fatality
rates in some states being higher than the national average, the Cabinet secretary on Saturday urged 12 states and UTs to analyse
mortalities district and hospital-wise to identify critical areas of intervention
At a high-level review meet, the secretary also exhorted them to ensure optimal utilisation of RT-PCR testing capacity, while underlining
the need for ensuring that no symptomatic negative case tested in rapid antigen examination is missed, and all such cases mandatorily
undergo RT-PCR test, the Union Health Ministry said.During the meeting chaired by the cabinet secretary, the minister of commerce and
industry addressed these states and UTs and reviewed the oxygen availability there.The 12 states and Union Territories that participated in
the virtual meet included Maharashtra, Karnataka, Andhra Pradesh, Uttar Pradesh, Tamil Nadu, Odisha, Chandigarh, Telangana, Kerala, Delhi,
Punjab and West Bengal, the health ministry said."About 80 percent of the COVID-19 caseload in the country is concentrated in these states
and UTs," it said."The Minister of Commerce and Industry specifically requested them to focus on analysing district-level and health
facility-level status and effectively plan and manage logistical issues related to oxygen availability," the health ministry said.The
country's COVID-19 tally had crossed the 20 lakh on 7 August, while it exceeded 30 lakh cses on 23 August, 40 lakh on 5 September, and it
went past 50 lakh on 16 September.According to the Indian Council of Medical Research, a cumulative 6,24,54,254 COVID-19 samples have been
followed by 8,685 from Tamil Nadu, 7,808 from Karnataka, 5,244 from Andhra Pradesh.With inputs from PTIFind latest and upcoming tech gadgets
online on https://www.reviewcomparepurchase.com Get technology news, gadgets reviews - ratings
Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
